Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities research analysts at Jefferies Group issued their Q1 2018 earnings estimates for Esperion Therapeutics in a report issued on Tuesday. Jefferies Group analyst M. Yee anticipates that the biopharmaceutical company will earn ($1.95) per share for the quarter. Jefferies Group has a “Buy” rating and a $85.00 price objective on the stock. Jefferies Group also issued estimates for Esperion Therapeutics’ Q2 2018 earnings at ($2.03) EPS, Q3 2018 earnings at ($2.20) EPS and Q4 2018 earnings at ($2.36) EPS.

Other research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 4th. Stifel Nicolaus reissued a “buy” rating and issued a $70.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Northland Securities reissued a “buy” rating and issued a $72.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Deutsche Bank AG set a $64.00 price target on shares of Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, Zacks Investment Research raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $58.92.

ILLEGAL ACTIVITY NOTICE: “Esperion Therapeutics, Inc. (ESPR) Expected to Post Q1 2018 Earnings of ($1.95) Per Share” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/09/esperion-therapeutics-inc-espr-expected-to-post-q1-2018-earnings-of-1-95-per-share.html.

Shares of Esperion Therapeutics (ESPR) traded up $0.06 during trading hours on Wednesday, reaching $47.66. 62,046 shares of the company’s stock traded hands, compared to its average volume of 519,929. Esperion Therapeutics has a 1 year low of $9.51 and a 1 year high of $57.40.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the previous year, the company earned ($0.77) EPS.

A number of institutional investors have recently bought and sold shares of the business. US Bancorp DE lifted its stake in Esperion Therapeutics by 1.1% in the second quarter. US Bancorp DE now owns 9,856 shares of the biopharmaceutical company’s stock worth $457,000 after purchasing an additional 104 shares during the last quarter. American International Group Inc. lifted its stake in Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 584 shares during the last quarter. Voya Investment Management LLC lifted its stake in Esperion Therapeutics by 12.7% in the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after purchasing an additional 806 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in Esperion Therapeutics by 3.0% in the second quarter. TIAA CREF Investment Management LLC now owns 39,074 shares of the biopharmaceutical company’s stock worth $1,808,000 after purchasing an additional 1,148 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in Esperion Therapeutics by 5.3% in the second quarter. Alliancebernstein L.P. now owns 30,070 shares of the biopharmaceutical company’s stock worth $1,392,000 after purchasing an additional 1,500 shares during the last quarter. 90.05% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.